Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a morphologically proven diagnosis AML and both the two following criteria: Age \> 50 years and £ 70 years. Not previously treated for their disease.~* ECOG performance status 0 to 3~* Negative serology HIV, HBV and HBC (except post vaccination)~* Serum creatinin inf 2.5N; AST and ALT inf 2.5N; total bilirubin inf 2N~* Cardiac function determined by radionucleide or echography within normal limits.~* Negative serum pregnancy test within one week before treatment for women of child bearing potential.~* Signed informed consent.~Exclusion Criteria:~* M3-AML~* AML following previously know myeloproliferative syndrome.~* Known central nervous system involvement.~* Uncontrolled infection~* Other active malignancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A Daunorubicin and Cytarabine (Type: ACTIVE_COMPARATOR): Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
- Arm B Daunorubicin and Cytarabine and Mylotarg (Type: EXPERIMENTAL): Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).